The new financial year is only a few weeks away.
I think that makes this a good time to look for ASX shares that could be best buys before FY27 begins.
The three shares in this article have strong long-term opportunities and I think they could be worth considering for investors.
Image source: Getty Images
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix Pharmaceuticals is one ASX share I would buy for FY27.
The company operates in radiopharmaceuticals, which is one of the more interesting areas of healthcare in my view. It is focused on products that can help detect and treat cancer more precisely.
That is the part of the story I find most compelling. Cancer care is moving towards better targeting, earlier detection, and more personalised treatment. Telix is exposed to that shift through imaging products, targeted therapies, and a growing pipeline.
This is not a simple healthcare stock. It carries clinical, regulatory, manufacturing, and commercial risks. The market can also change its view quickly when expectations around high-growth biotech companies move.
But I think Telix has already moved beyond being a purely speculative story. It has commercial products, global ambitions, and a pipeline that could become more valuable over time if management keeps executing.
FY27 could be another important year for the company as investors look for more evidence that Telix can turn its scientific position into durable earnings growth.
Catapult Sports Ltd (ASX: CAT)
Catapult Sports is another ASX share I think could be worth buying before FY27.
The company sells technology used by elite sporting teams to understand performance, training, tactics, workload, and recovery.
What interests me is how embedded this kind of technology can become inside a professional sports organisation. Clubs want information that helps coaches plan sessions, medical teams manage injury risk, analysts review performance, and players prepare more effectively.
That daily-use element is important.
I also think Catapult is becoming a more complete sports technology platform. Wearables remain part of the story, but the opportunity is broader across video, athlete monitoring, analysis, and workflow tools.
Elite sport is also global. Football, basketball, rugby, cricket, American football, and many other codes all want better information. The company does not need to win every team in every league to build a much larger business. It just needs to keep deepening its value with customers and expanding carefully.
ResMed Inc (ASX: RMD)
ResMed is the third ASX share I would buy for FY27.
The sleep health giant has been under pressure, but I think the long-term case remains attractive.
ResMed sells devices, masks, accessories, software, and connected care products for sleep apnoea and other respiratory conditions. But treatment does not necessarily end with a single sale. Patients often need replacement masks, ongoing support, monitoring, and long-term therapy management.
Sleep apnoea remains significantly underdiagnosed, but greater awareness of the condition has been encouraging more people to seek diagnosis over time. ResMed's leadership position, strong brand, scale, distribution, and product depth position it to win if that continues.
Foolish takeaway
The start of a new financial year can be a useful moment to reassess what kind of businesses are worth owning for the years ahead.
I am drawn to companies that are solving real problems in markets that still have room to grow. Cancer detection and treatment, elite sports performance, and sleep health all fit that description.
I think each of these ASX shares has enough long-term potential to be worth buying before the new financial year begins.
